Chiusura precedente | 61,02 |
Aperto | 61,33 |
Denaro | N/D x N/D |
Lettera | N/D x N/D |
Min-Max giorno | 61,33 - 61,63 |
Intervallo di 52 settimane | 61,33 - 89,58 |
Volume | |
Media Volume | 59.721 |
Capitalizzazione | N/D |
Beta (5 anni mensile) | 0,20 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | N/D |
Prossima data utili | 25 apr 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr